<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OMEPRAZOLE AND SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span>- omeprazole and sodium bicarbonate capsule </strong><br>Par Pharmaceutical Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<br>These highlights do not include all the information needed to use Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Capsules safely and effectively. See full prescribing information for Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Capsules.<br>Initial U.S. Approval: 2004</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> ( <a href="#inv-e15c2f67-bff8-4e62-af2d-c6bdcce9a671">5.6</a>)          05/2011 </p>
<p class="Highlighta">Warnings and Precautions, Diminished anti-platelet activity of clopidogrel ( <a href="#_Ref">5.5</a>)  11/2011 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> Capsules is a proton pump inhibitor indicated for: </p>
<dl>
<dt>•</dt>
<dd>Short-term treatment of active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> (<a href="#inv-a2ad5ab5-da3f-4a8a-b65d-8a697069fa9b">1.1</a>)</dd>
<dt>•</dt>
<dd>Short-term treatment of active benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> (<a href="#inv-d4aac76f-db9b-45a9-b20f-f6f749fe20cc">1.2</a>)</dd>
<dt>•</dt>
<dd>Treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) (<a href="#inv-64c575db-4b1a-4136-aa97-ef144ea03bda">1.3</a>)</dd>
<dt>•</dt>
<dd>Maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> (<a href="#inv-a314664c-504b-4a09-b2d5-6df32e90d8d8">1.4</a>)</dd>
</dl>
<p class="Highlighta">The safety and effectiveness of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> capsules in pediatric patients (&lt;18 years of age) have not been established. ( <a href="#inv-2ee05dab-36a4-4af7-b566-4358cc83901e">8.3</a>) </p>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Short-Term Treatment of Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span>: 20 mg once daily for 4 weeks (some patients may require an additional 4 weeks of therapy (<a href="#inv-c9df644e-12a0-4da8-acce-da07022113f7">14.1</a>) (<a href="#_Ref">2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span>: 40 mg once daily for 4 to 8 weeks (<a href="#_Ref">2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) (<a href="#_Ref">2</a>)  Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> (with no <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">esophageal erosions</span>): 20 mg once daily for up to 4 weeks  <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span>: 20 mg once daily for 4 to 8 weeks</dd>
<dt>•</dt>
<dd>Maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span>: 20 mg once daily (<a href="#_Ref">2</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is available as a capsule in 20 mg and 40 mg strengths (<a href="#inv-b3398a91-b0fa-42ca-8f6e-d94a4b7d3678">3</a>)</dd>
<dt>•</dt>
<dd>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> 20 mg Capsules: Each capsule consists of a white opaque body printed with par/397 in black ink and light blue opaque cap.</dd>
<dt>•</dt>
<dd>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> 40 mg Capsules: Each capsule consists of a white opaque body printed with par/455 in black ink and blue opaque cap.</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any components of the formulation (<a href="#inv-ebe41193-02a0-44ef-bef7-e6903babf2bc">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Concomitant <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">Gastric Malignancy</span>: Symptomatic response to therapy with omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> capsules does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span> (<a href="#_Ref">5.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic Gastritis</span>: Has been observed in gastric corpus biopsies from patients treated long-term with omeprazole (<a href="#_Ref">5.2</a>)</dd>
<dt>•</dt>
<dd>Buffer Content:  contains sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (<a href="#_Ref">5.3</a>)</dd>
<dt>•</dt>
<dd>Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span>: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist, or spine. (<a href="#_Ref">5.4</a>) </dd>
<dt>•</dt>
<dd>Diminished anti-platelet activity of clopidogrel due to impaired CYP2C19 function by 80mg omeprazole (<a href="#inv-4026ce2f-c02f-4ffe-8ffa-49360afa2b31">5.5</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> has been reported rarely with prolonged treatment with PPIs (<a href="#inv-e15c2f67-bff8-4e62-af2d-c6bdcce9a671">5.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical, Inc. at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
<p class="Highlighta">Most common adverse reactions (incidence ≥ 2%) are: </p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> ( <a href="#_Ref">6</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> can prolong their elimination. Monitor to determine the need for possible dose adjustments when taken with omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (<a href="#_Ref">7</a>)</dd>
<dt>•</dt>
<dd>Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increase in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">7</a>)</dd>
<dt>•</dt>
<dd>Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts and digoxin): Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> may interfere with absorption due to inhibition of gastric acid secretion <a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">(7</a>)</dd>
<dt>•</dt>
<dd>Voriconazole: May increase plasma levels of omeprazole (<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">7</a>)</dd>
<dt>•</dt>
<dd>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> may reduce plasma levels of atazanavir and nelfinavir (<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">7</a>)</dd>
<dt>•</dt>
<dd>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> may increase serum levels of tacrolimus, voriconazole, saquinavir, and clarithromycin (<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">7</a>)</dd>
<dt>•</dt>
<dd>Coadministration of clopidogrel with 80mg omeprazole may reduce the pharmacological activity of clopidogrel if given concomitantly or if given 12 hours apart (<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">7</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy: Based upon animal data, may cause fetal harm (<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">8.1</a>)</dd>
<dt>•</dt>
<dd>The safety and effectiveness of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> in pediatric patients less than18 years of age have not been established. (<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">8.4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Consider dose reduction, particularly for maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> (<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">12.3</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> </a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> </a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">Special Populations </a></h2>
<h2><a href="#section-2.2" class="toc">Administration of Capsules </a></h2>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Concomitant <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">Gastric Malignancy</span> </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic gastritis</span> </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Buffer Content </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Diminished Anti-platelet Activity of clopidogrel due to Impaired CYP2C19 Function of Omeprazole</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drugs for which gastric pH can affect bioavailability</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drugs metabolized by cytochrome P450 (CYP)</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Antiretroviral Agents </a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Antimicrobials </a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Clopidogrel</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Tacrolimus </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Asian Population </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action Section</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics </a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">Special Populations </a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis and Mutagenesis and Impairment Of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Pharmacology and/or Toxicology Section </a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Disease </a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> </a></h2>
<h2><a href="#section-13.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) </a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Long Term Maintenance Treatment of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> </a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">Storage </a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">FDA-APPROVED PATIENT LABELING </a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="inv-1907e163-51d0-49df-945c-4324c8547c06"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-a2ad5ab5-da3f-4a8a-b65d-8a697069fa9b"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> </h2>
<p class="First">Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is indicated for short-term treatment of active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. [See <span class="Bold">Clinical Studies </span>(<a href="#inv-c9df644e-12a0-4da8-acce-da07022113f7">14.1</a>)]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-d4aac76f-db9b-45a9-b20f-f6f749fe20cc"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> </h2>
<p class="First">Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is indicated for short-term treatment (4 to 8 weeks) of active benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>. (See <span class="Bold">Clinical Studies </span>(<a href="#inv-9b1e446d-cabb-4213-b3cf-5425c9b66fbf">14.2</a>)]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-64c575db-4b1a-4136-aa97-ef144ea03bda"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-a4db9831-d31d-4d23-bd22-4f29794f3ecd"></a><a name="section-1.3.1"></a><p></p>
<h3><span class="Bold">Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> </span></h3>
<p class="First">Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and other symptoms associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. [See <span class="Bold"> Clinical Studies </span>(<a href="#inv-dd8b66ee-aef7-4cfd-8363-f520810e0ae9">14.3</a>)]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-1354f463-0d82-43d3-bd65-2555a4ba2841"></a><a name="section-1.3.2"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> </span></h3>
<p class="First">Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is indicated for the short-term treatment (4 to 8 weeks) of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> which has been diagnosed by endoscopy.</p>
<p>The efficacy of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> used for longer than 8 weeks in these patients has not been established. If a patient does not respond to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. If there is recurrence of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> or <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> symptoms (e.g., <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>), additional 4 to 8 week courses of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> may be considered. [See <span class="Bold"> Clinical Studies </span>(<a href="#inv-dd8b66ee-aef7-4cfd-8363-f520810e0ae9">14.3</a>)]</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-a314664c-504b-4a09-b2d5-6df32e90d8d8"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Maintenance of Healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></h2>
<p class="First">Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> capsules is indicated to maintain healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>. Controlled studies do not extend beyond 12 months <span class="Bold">. </span>[See <span class="Bold">Clinical Studies </span>(<a href="#inv-50c7f20c-8404-4628-8f77-f15057ea525b">14.4</a>)]</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="inv-461c6d91-23bc-453a-8b21-c627e85cac19"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is available as a capsule in 20 mg and 40 mg strengths of omeprazole for adult use. Directions for use for each indication are summarized in <span class="Bold">Table 1</span>. All recommended doses throughout the labeling are based upon omeprazole.</p>
<p>Since both the 20 mg and 40 mg <span class="Bold">capsules </span>contain the same amount of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (1100 mg), two capsules of 20 mg are <span class="Bold">not </span>equivalent to one capsule of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> 40 mg; therefore, two 20 mg capsules of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> should not be substituted for one capsule of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> 40 mg.</p>
<p>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> should be taken on an empty stomach at least one hour before a meal.</p>
<a name="_Refinv-8870efee-c2ee-4dc1-91a6-5b6edb88"></a><table width="100%">
<caption><span>Table 1: Recommended Doses of Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> by Indication for Adults 18 Years and Older</span></caption>
<col width="32%">
<col width="25%">
<col width="29%">
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="3" valign="top">*Most patients heal within 4 weeks. Some patients may require an additional 4 weeks of therapy. [See Clinical Studies ( <a href="#inv-c9df644e-12a0-4da8-acce-da07022113f7">14.1</a>)]</td></tr>
<tr><td class="Botrule" align="left" colspan="3" valign="top">**For additional information, [See Clinical Studies (14)]</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="3" valign="top">+ For additional information, [See INDICATIONS AND USAGE section (1)]</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">	I<span class="Bold">	ndication      </span></p></td>
<td class="Botrule Rrule Toprule"><p class="First">	R<span class="Bold">	ecommended Dose      </span></p></td>
<td class="Botrule Rrule Toprule"><p class="First">	F<span class="Bold">	requency      </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Short-Term Treatment of Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></p></td>
<td class="Botrule Rrule"><p class="First">20 mg</p></td>
<td class="Botrule Rrule"><p class="First">Once daily for 4 weeks<span class="Sup">*,+</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Benign <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> </p></td>
<td class="Botrule Rrule"><p class="First">40 mg </p></td>
<td class="Botrule Rrule"><p class="First">Once daily for 4-8 weeks <span class="Sup">**,+</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux</span>               Disease (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>                   (with no <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">esophageal erosions</span>) </p></td>
<td class="Botrule Rrule"><p class="First">         20 mg</p></td>
<td class="Botrule Rrule"><p class="First">         Once daily for up to 4 weeks+                            </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">    <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span></p></td>
<td class="Botrule Rrule"><p class="First">20 mg</p></td>
<td class="Botrule Rrule"><p class="First">Once daily for 4-8 weeks<span class="Sup">+</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Maintenance of Healing of           <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> </p></td>
<td class="Botrule Rrule"><p class="First">20 mg</p></td>
<td class="Botrule Rrule"><p class="First">Once daily**</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">Reduction of Risk          of Upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal Bleeding</span> in   Critically Ill Patients         (40 mg oral          suspension only)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">40 mg</p></td>
<td class="Botrule Rrule" align="center"><p class="First">40 mg initially followed by          40 mg 6-8 hours          later and 40 mg daily          thereafter for         14 days**</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-ce1cd692-912f-4c87-8703-9b4ea3457ac1"></a><a name="section-2.1"></a><p></p>
<h2>Special Populations </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-5d1d6360-a26e-4ff7-8c34-c84bddbd0e40"></a><a name="section-2.1.1"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></h3>
<p class="First">Consider dose reduction, particularly for maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>. [See <span class="Bold"> Clinical Pharmacology </span>(<a href="#inv-ebe41193-02a0-44ef-bef7-e6903babf2bc">12.3</a>)<span class="Bold">]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-a2ecda2a-2048-48d0-9481-b2af534669ea"></a><a name="section-2.2"></a><p></p>
<h2>Administration of Capsules </h2>
<p class="First">Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Capsules should be swallowed intact with water. DO NOT USE OTHER LIQUIDS. DO NOT OPEN CAPSULE AND SPRINKLE CONTENTS INTO FOOD.</p>
<p><span class="Bold">Use with clopidogrel</span></p>
<p>Avoid concomitant use of clopidogrel and omeprazole. Coadministration of clopidogrel with 80mg omeprazole, a proton pump inhibitor that is an inhibitor if CYP2C19, reduces the pharmacological activity of clopidogrel if given concomitantly or if given 12 hours apart [see <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#inv-e15c2f67-bff8-4e62-af2d-c6bdcce9a671">5.6</a>) and <span class="Bold">Drug Interactions</span> (<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">7</a>) ].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="inv-b4d25be5-f709-45e2-a6ab-413f0225036f"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="inv-ed241891-eca4-4d51-99da-a6948d8432c1"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any components of the formulation. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="inv-48f16af8-6308-4be6-a2d1-ed5baac0532e"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-cf42b7ae-6e62-422c-b223-cfeb00fe5429"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Concomitant <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">Gastric Malignancy</span> </h2>
<p class="First">Symptomatic response to therapy with omeprazole does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-de8fc298-37ec-4ffd-aaed-729a3190f12e"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic gastritis</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">Atrophic gastritis</span> has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-c01c4169-4ae3-4a8f-9a8c-270f22da5883"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Buffer Content </h2>
<p class="First">Each omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> capsule contains 1100 mg (13 mEq) of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. The total content of sodium in each capsule is 304 mg.</p>
<p>The sodium content of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> products should be taken into consideration when administering to patients on a sodium restricted diet.</p>
<p>Because omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> products contain sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, they should be used with caution in patients with Bartter’s syndrome, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, and problems with acid-base balance. Long-term administration of <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> with calcium or milk can cause milk-alkali syndrome.</p>
<p>Chronic use of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> may lead to systemic <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span> and increased sodium intake can produce <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-fb1b916d-d262-471f-858a-14d63fe4723f"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></h2>
<p class="First">Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist, or spine. The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> should be managed according to the established treatment guidelines. [See <span class="Bold">DOSAGE AND ADMINISTRATION</span> ( <a href="#_Ref">2</a>) and <span class="Bold">ADVERSE REACTIONS</span> (<a href="#_Ref">6.2</a>)] </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-4026ce2f-c02f-4ffe-8ffa-49360afa2b31"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Diminished Anti-platelet Activity of clopidogrel due to Impaired CYP2C19 Function of Omeprazole</h2>
<p class="First">Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications, such as omeprazole, that interfere with CYP2C19 activity. Avoid concomitant use of clopidogrel and omeprazole. Coadministration of clopidogrel with 80mg omeprazole, a proton pump inhibitor that is an inhibitor of CYP2C19, reduces the pharmacological activity of clopidogrel if given concomitantly or if given 12 hours apart [ see <span class="Bold">Drug Interactions</span> (<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">7</a>) ].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-e15c2f67-bff8-4e62-af2d-c6bdcce9a671"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span>, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. In most patients, treatment of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> recquired magnesium replacement and discontinuation of the PPI.</p>
<p>For patients expected to be on prolonged treatment or who take PPI’s with medications such as digoxin or drugs that may cause <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> (e.g., diuretics), healthcare professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically. [See <span class="Bold">ADVERSE REACTIONS</span> (<a href="#inv-cb0149ac-d042-425b-a401-c61a6b4641a1">6.2</a>) ].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="inv-b3398a91-b0fa-42ca-8f6e-d94a4b7d3678"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-3036b750-df59-4bb0-b619-2c9af01432b9"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>In the U.S. clinical trial population of 465 patients, the adverse reactions summarized in Table 2 were reported to occur in 1% or more of patients on therapy with omeprazole. Numbers in parentheses indicate percentages of the adverse reactions considered by investigators as possibly, probably or definitely related to the drug.</p>
<a name="_Refinv-ea290505-72b5-4fcb-b746-7683a3f7"></a><table width="100%">
<caption><span>Table 2: Adverse Reactions Occurring In 1% or More of Patients on Omeprazole Therapy</span></caption>
<col width="19%">
<col width="22%">
<col width="18%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	(n<span class="Bold">	 = 465)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	P<span class="Bold">	lacebo      </span>	 (<span class="Bold">	n = 64)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	R<span class="Bold">	anitidine      </span>	(n<span class="Bold">	 = 195)      </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">6.9 (2.4)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7.7 (2.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.0 (1.9)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.1 (1.6)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.1 (0.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.4 (0.4)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.2 (0.9)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.1 (0.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">URI </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.5 (0.6)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.6 (1.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.5 (0.4)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.5 (0.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.5 (1.1)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.1 (0.9)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.1 (0.2)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.6 (1.6)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.5 (1.0)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.5</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Table 3</span> summarizes the adverse reactions that occurred in 1% or more of omeprazole-treated patients from international double-blind, and open-label clinical trials in which 2,631 patients and subjects received omeprazole.</p>
<a name="_Refinv-c12ff791-28a2-4107-9d16-4d004517"></a><table width="100%">
<caption><span>Table 3: Incidence of Adverse Reactions ≥ 1%Causal Relationship not Assessed</span></caption>
<col width="23%">
<col width="23%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	(n<span class="Bold">	 = 2631)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	P<span class="Bold">	lacebo      </span>	(n<span class="Bold">	 = 120)      </span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First">Body as a Whole, site unspecified </p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>            <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">5.2          1.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.3         0.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Digestive System </p></td>
<td class="Botrule Rrule"><p class="First"> </p></td>
<td class="Botrule Rrule"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>             <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>             <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span>             <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>             <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>             Acid <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.5         3.7         2.7         4.0         3.2         1.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.8         2.5         5.8         6.7         10.0         3.3</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First">Nervous System/Psychiatric </p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-cb0149ac-d042-425b-a401-c61a6b4641a1"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience </h2>
<p class="First">The following adverse reactions have been identified during post-approval use of omeprazole. Because these reactions are voluntarily reported from a population of uncertain size, it is not always possible to reliably estimate their actual frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Body as a Whole</span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (see also <span class="Italics">Skin </span>below), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
<p><span class="Italics">Cardiovascular</span></p>
<p><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> or angina, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, elevated blood pressure, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>.</p>
<p><span class="Italics">Gastrointestinal</span></p>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> (some fatal), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable colon</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, fecal discoloration, <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>, mucosal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of the tongue, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> and abdominal <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>. During treatment with omeprazole, gastric fundic gland <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> have been noted rarely. These <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> are benign and appear to be reversible when treatment is discontinued. Gastroduodenal carcinoids have been reported in patients with Zollinger-Ellison syndrome on long-term treatment with omeprazole. This finding is believed to be a manifestation of the underlying condition, which is known to be associated with such tumors.</p>
<p><span class="Italics">Hepatic</span></p>
<p>Mild and, rarely, marked elevations of liver function tests [ALT (SGPT), AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), γ-glutamyl transpeptidase, alkaline phosphatase, and bilirubin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)]. In rare instances, overt liver disease has occurred, including hepatocellular, cholestatic, or mixed <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> (some fatal), <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> (some fatal), and <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>.</p>
<p><span class="Italics">Metabolic/Nutritional</span></p>
<p><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
<p><span class="Italics">Musculoskeletal</span></p>
<p><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>.</p>
<p><span class="Italics">Nervous System/Psychiatric</span></p>
<p><span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">Psychic disturbances</span> including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, dream abnormalities; <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>; and hemifacial <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>.</p>
<p><span class="Italics">Respiratory</span></p>
<p><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>, pharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><span class="Italics">Skin</span></p>
<p>Severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">generalized skin reactions</span> including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN; some fatal), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (some severe); <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> and/or <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> (some with rechallenge); <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">skin inflammation</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>.</p>
<p><span class="Italics">Special Senses</span></p>
<p><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>.</p>
<p><span class="Italics">Ocular</span></p>
<p><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, ocular irritation, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye syndrome</span>, <span class="product-label-link" type="condition" conceptid="372914" conceptname="Optic atrophy">optic atrophy</span>, anterior <span class="product-label-link" type="condition" conceptid="373487" conceptname="Ischemic optic neuropathy">ischemic optic neuropathy</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>.</p>
<p><span class="Italics">Urogenital</span></p>
<p>Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> (some with positive rechallenge), <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, microscopic <span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">pyuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, elevated serum creatinine, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4270932" conceptname="Pain in testicle">testicular pain</span>, and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>.</p>
<p><span class="Italics">Hematologic</span></p>
<p>Rare instances of <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> (some fatal), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, leucocytosis, and <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> have been reported.</p>
<p>The incidence of clinical adverse experiences in patients greater than 65 years of age was similar to that in patients 65 years of age or less.</p>
<p>Additional adverse reactions that could be caused by sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> include <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="inv-5becca46-fb6a-45cd-b038-4adfead0e5de"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-53e301c0-0012-432c-84e9-29b20d5f5418"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drugs for which gastric pH can affect bioavailability</h2>
<p class="First">Because of its inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, iron salts and digoxin). In the clinical efficacy trials, antacids were used concomitantly with the administration of omeprazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-c546b699-1885-4f84-9b1f-9349432b7ef8"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drugs metabolized by cytochrome P450 (CYP)</h2>
<p class="First">Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver. There have been reports of increased INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly. Increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time may lead to abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients treated with proton pump inhibitors and warfarin may need to be monitored for increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
<p>Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P-450 system (e.g., cyclosporine, disulfiram, benzodiazepines). Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</p>
<p>Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure. Dose adjustment of omeprazole is not normally required. When voriconazole (400 mg every 12 hours for one day, then 200 mg for 6 days) was given with omeprazole (40 mg once daily for 7 days) to healthy subjects, it significantly increased the steady-state C <span class="Sub">max</span> of AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-3885ca38-5d26-443f-8869-6f87db5f4b0d"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Antiretroviral Agents </h2>
<p class="First">Concomitant administration of atazanavir and proton pump inhibitors is not recommended. Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect.</p>
<p>Omeprazole has been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19. For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, twice daily), and omeprazole (40 mg, daily), AUC was decreased by 36% and 92%, C <span class="Sub">max</span> by 37% and 89% and C<span class="Sub">min</span> by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of atazanavir (400 mg, daily) and omeprazole (40 mg, daily, 2 hours before atazanavir), AUC was decreased by 94%, C<span class="Sub">max</span> by 96%, and C<span class="Sub">min</span> by 95%. Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended. For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in C<span class="Sub">max</span> by 75% and in C<span class="Sub">min</span> by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) twice daily for 15 days with omeprazole 40 mg daily co-administered days 11 to 15. Dose reduction of saquinavir should be considered from the safety perspective for individual patients. There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-a92f9b94-ea98-45fc-bbdb-5b338ed5ffc8"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Antimicrobials </h2>
<p class="First">Omeprazole 40 mg daily was given in combination with clarithromycin 500 mg every 8 hours to healthy adult male subjects. The steady state plasma concentrations of omeprazole were increased (C <span class="Sub">max</span>, AUC0-24, and T<span class="Sub">1/2</span> increases of 30%, 89% and 34% respectively) by the concomitant administration of clarithromycin. The observed increases in omeprazole plasma concentration were associated with the following pharmacological effects. The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when co-administered with clarithromycin. </p>
<p>The plasma levels of clarithromycin and 14-hydroxyclarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean C <span class="Sub">max</span> was 10% greater, the mean C<span class="Sub">min</span> was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14-hydroxyclarithromycin, the mean C<span class="Sub">max</span> was 45% greater, the mean C<span class="Sub">min</span> was 57% greater, and the mean AUC0-8 was 45% greater. Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole.</p>
<a name="_Refinv-ca8f918d-91f7-41b3-8256-11951566"></a><table width="100%">
<caption><span>Table 4: Clarithromycin Tissue Concentrations 2 hours after Dose<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Tissue</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Clarithromycin</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Clarithromycin + Omeprazole</span></th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Mean ± (ug/g)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Antrum </p></td>
<td class="Botrule Rrule Toprule"><p class="First">10.48 ± 2.01 (n=5)</p></td>
<td class="Botrule Rrule Toprule"><p class="First">19.96 ± 4.71 (n=5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Fundus</p></td>
<td class="Botrule Rrule"><p class="First">20.81 ± 7.64 (n=5)</p></td>
<td class="Botrule Rrule"><p class="First">24.25 ± 6.37 (n=5)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Mucus</p></td>
<td class="Botrule Rrule"><p class="First">4.15 ± 7.74 (n=4)</p></td>
<td class="Botrule Rrule"><p class="First">39.29 ± 32.79 (n=4)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-243773be-0616-4e37-a54a-4e6576dc7370"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Clopidogrel</h2>
<p class="First">Omeprazole is an inhibitor of CYP2C19 enzyme. Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of omeprazole 80mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition [see <span class="Bold">WARNING AND PRECAUTIONS</span> (<a href="#inv-e15c2f67-bff8-4e62-af2d-c6bdcce9a671">5.6</a>)].</p>
<p>In a crossover clinical study, 72 healthy subjects were administered clopidogrel (300mg loading dose followed by 75mg per day) alone and with omeprazole (80mg at the same time as clopidogrel) for 5 days. The exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5) when clopidogrel and omeprazole were administered together.</p>
<p>The active metabolite of clopidogrel selectively and irreversibly inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor, thereby inhibiting platelet aggregation. The mean inhibition of platelet aggregation at 5 mcM ADP was diminished by 39% (Day 1) and 21% (Day 5) when clopidogrel and omeprazole were administered together.</p>
<p>In another study, 72 healthy subjects were given the same doses of clopidogrel and 80mg omeprazole but the drugs were administered 12 hours apart; the results were similar, indicating that administering clopidogrel and omeprazole at different times does not prevent their interaction [see <span class="Bold">WARNINGS AND PRECAUTIONS</span> (<a href="#inv-e15c2f67-bff8-4e62-af2d-c6bdcce9a671">5.6</a>)].</p>
<p>There are no adequate combination studies of a lower dose of omeprazole or higher dose of clopidogrel in comparison with the approved doses of clopidogrel.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-e5500500-aeab-40a5-b184-07db3d0cfaad"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Tacrolimus </h2>
<p class="First">Concomitant administration of omeprazole and tacrolimus may increase the serum levels of tacrolimus.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="inv-cf22bfa0-ecc7-48a4-9e93-fd2a32399ed4"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="inv-b7d2364b-78bd-4d5e-b578-bf1de398e5e1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-f288e18c-5845-4a4a-878a-485fd3ee41b4"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">Pregnancy Category C </span></h3>
<p class="First">There are no adequate and well-controlled studies on the use of omeprazole in pregnant women. The vast majority of reported experience with omeprazole during human pregnancy is first trimester exposure and the duration of use is rarely specified, eg, intermittent vs. chronic. An expert review of published data on experiences with omeprazole use during pregnancy by TERIS – the Teratogen Information System – concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as fair). <span class="Sup">1</span></p>
<p>Three epidemiological studies compared the frequency of congenital abnormalities among infants born to women who used omeprazole during pregnancy to the frequency of abnormalities among infants of women exposed to H2-receptor antagonists or other controls. A population-based prospective cohort epidemiological study from the Swedish Medical Birth Registry, covering approximately 99% of pregnancies, reported on 955 infants (824 exposed during the first trimester with 39 of these exposed beyond first trimester, and 131 exposed after the first trimester) whose mothers used omeprazole during pregnancy. <span class="Sup">2</span> In utero exposure to omeprazole was not associated with increased risk of any malformation (odds ratio 0.82, 95% CI 0.50-1.34), low birth weight or low Apgar score. The number of infants born with <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defects</span> and the number of stillborn infants was slightly higher in the omeprazole exposed infants than the expected number in the normal population. The author concluded that both effects may be random.</p>
<p>A retrospective cohort study reported on 689 pregnant women exposed to either H2-blockers or omeprazole in the first trimester (134 exposed to omeprazole). <span class="Sup">3</span> The overall malformation rate was 4.4% (95% CI 3.6-5.3) and the malformation rate for first trimester exposure to omeprazole was 3.6% (95% CI 1.5-8.1). The relative risk of malformations associated with first trimester exposure to omeprazole compared with nonexposed women was 0.9 (95% CI 0.3-2.2). The study could effectively rule out a relative risk greater than 2.5 for all malformations. Rates of preterm delivery or <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> did not differ between the groups. </p>
<p>A controlled prospective observational study followed 113 women exposed to omeprazole during pregnancy (89% first trimester exposures) <span class="Sup">4</span>. The reported rates of major congenital malformations was 4% for the omeprazole group, 2% for controls exposed to nonteratogens, and 2.8% in disease-paired controls (background incidence of major malformations 1-5%). Rates of spontaneous and elective abortions, preterm deliveries, gestational age at delivery, and mean birth weight did not differ between the groups. The sample size in this study has 80% power to detect a 5-fold increase in the rate of major malformation. </p>
<p>Several studies have reported no apparent adverse short term effects on the infant when single dose oral or intravenous omeprazole was administered to over 200 pregnant women as premedication for cesarean section under general anesthesia.</p>
<p>Reproduction studies conducted with omeprazole in rats at oral doses up to 28 times the human dose of 40 mg/day (based on body surface area) and in rabbits at doses up to 28 times the human dose (based on body surface area) did not show any evidence of terogenicity. In pregnant rabbits, omeprazole at doses about 2.8 to 28 times the human dose of 40mg/day, (based on body surface area) produced dose-related increases in embryo-lethality, fetal resorptions, and pregnancy loss. In rats treated with omeprazole at doses about 2.8 to 28 times the human dose (based on body surface area), dose-related embryo/fetal toxicity and postnatal developmental toxicity occurred in offspring. [See <span class="Bold"> Animal Toxicology and/or Pharmacology </span>(<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">13.2</a>)]. </p>
<p>There are no adequate and well-controlled studies in pregnant women. Because animal studies and studies in humans cannot rule out the possibility of harm, omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> should be used during pregnancy only if the potential benefit to pregnant women justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="inv-2ee05dab-36a4-4af7-b566-4358cc83901e"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Omeprazole concentrations have been measured in breast milk of a woman following oral administration of 20 mg. The peak concentration of omeprazole in breast milk was less than 7% of the peak serum concentration. The concentration will correspond to 0.004 mg of omeprazole in 200 mL of milk. Because omeprazole is excreted in human milk, because of the potential for serious adverse reactions in nursing infants from omeprazole, and because of the potential for tumorigenicity shown for omeprazole in rat carcinogenicity studies, a decision should be taken to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. In addition, sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> should be used with caution in nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="inv-4a8d570d-090f-4e44-b8b4-e01d49647628"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> have not been established in pediatric patients less than 18 years of age.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="inv-2025964c-73d8-4fdf-9f8c-ce8665d29100"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Omeprazole was administered to over 2000 elderly individuals ≥ 65 years of age) in clinical trials in the U.S. and Europe. There were no differences in safety and effectiveness between the elderly and younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>Pharmacokinetic studies with buffered omeprazole have shown the elimination rate was somewhat decreased in the elderly and bioavailability was increased. The plasma clearance of omeprazole was 250 mL/min (about half that of young subjects). The plasma half-life averaged one hour, about twice that in nonelderly, healthy subjects taking omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. However, no dosage adjustment is necessary in the elderly. (See <span class="Bold"> CLINICAL PHARMACOLOGY </span>(<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">12.3</a>)] </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-fd176d17-c2a2-4070-aad8-2a0979f1ebdc"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Consider dose reduction, particularly for maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>. [See <span class="Bold"> Clinical Pharmacology </span>(<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">12.3</a>)] </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-b3140b2b-4854-4549-9f8a-da7c3267d6f7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">No dose reduction is necessary. [See <span class="Bold"> Clinical Pharmacology </span>(<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">12.3</a>)] </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-96fe39eb-2093-4a32-b0e8-043ef3908ff4"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Asian Population </h2>
<p class="First">Recommended dose reduction, particularly for maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>. [See <span class="Bold"> Clinical Pharmacology </span>(<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">12.3</a>)] </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="inv-1b012996-4892-43a8-ad8d-ac801b2ffa2b"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Reports have been received of overdosage with omeprazole in humans. Doses ranged up to 2400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and other adverse reactions similar to those seen in normal clinical experience. (See <span class="Bold">ADVERSE REACTIONS </span>(<a href="#inv-5becca46-fb6a-45cd-b038-4adfead0e5de">6</a>)<span class="Bold">.</span> Symptoms were transient, and no serious clinical outcome has been reported when omeprazole was taken alone. No specific antidote for omeprazole overdosage is known. Omeprazole is extensively protein bound and is, therefore, not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive. </p>
<p>As with the management of any <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the possibility of multiple drug ingestion should be considered. For current information on treatment of any drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a certified Regional Poison Control Center should be contacted. Telephone numbers are listed in the Physicians’ Desk Reference (PDR) or local telephone book.</p>
<p>Single oral doses of omeprazole at 1350, 1339, and 1200 mg/kg were lethal to mice, rats, and dogs, respectively. Animals given these doses showed sedation, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">decreased activity</span>, body temperature, and <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and increased depth of respiration.</p>
<p>In addition, a sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may cause <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="inv-a6cb5672-4b57-4b57-8a0b-f7c5d692069a"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is a combination of omeprazole, a proton-pump inhibitor, and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, an antacid. Omeprazole is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 <span class="Italics">H</span>-benzimidazole, a racemic mixture of two enantiomers that inhibits gastric acid secretion. Its structural formula is C<span class="Sub">17</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O<span class="Sub">3</span>S, with a molecular weight of 345.42. The structural formula is:</p>
<div class="Figure">
<a name="ID0E3DBG"></a><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c43b7c1e-1eb6-48b4-ba73-56e274239ae2&amp;name=structure.jpg">
</div>
<p>Omeprazole is a white to off-white crystalline powder which melts with decomposition at about 155°C. It is a weak base, freely soluble in ethanol and methanol, and slightly soluble in acetone and isopropanol and very slightly soluble in water. The stability of omeprazole is a function of pH; it is rapidly degraded in acid media, but has acceptable stability under alkaline conditions.</p>
<p>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is supplied as as immediate-release capsules. Each capsule contains either 40 mg or 20 mg of omeprazole and 1100 mg of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> with the following excipients: croscarmellose sodium and magnesium stearate. The capsules consist of black iron oxide, D&amp;C Yellow #10, FD&amp;C Blue #1, FD&amp;C Red #3, FD&amp;C Red #40, gelatin and titanium dioxide. In addition the ink consists of D&amp;C Yellow #10 aluminum lake, iron oxide black, n-butyl alcohol, propylene glycol, FD&amp;C Blue #2 aluminum lake, FD&amp;C Red #40 aluminum lake, FD&amp;C Blue #1 aluminum lake and shellac glaze~45% (20% esterfied) in ethanol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="inv-81794218-4c48-4a2f-9580-def5fb54b54c"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="inv-8e56a731-c961-4b6e-9769-dfbe4740ae09"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action Section</h2>
<p class="First">Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Animal studies indicate that after rapid disappearance from plasma, omeprazole can be found within the gastric muscosa for a day or more.</p>
<p>Omeprazole is acid labile and thus rapidly degraded by gastric acid. Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> capsule is an immediate-release formulation that contains sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> which raises the gastric pH and thus protects omeprazole from acid degradation.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="inv-ede32dcf-5a58-4770-9ac6-de0732a2a971"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics </h2>
<p class="First"><span class="Italics">Enterochromaffin-like (ECL) Cell Effects </span></p>
<p>In 24-month carcinogenicity studies in rats, a dose-related significant increase in gastric <span class="product-label-link" type="condition" conceptid="4304399" conceptname="Carcinoid tumor">carcinoid tumors</span> and ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was observed in both male and female animals. [See <span class="Bold">Nonclinical Toxicology </span>(13.1)]. <span class="product-label-link" type="condition" conceptid="4304399" conceptname="Carcinoid tumor">Carcinoid tumors</span> have also been observed in rats subjected to fundectomy or long-term treatment with other proton pump inhibitors or high doses of H2-receptor antagonists. Human gastric biopsy specimens have been obtained from more than 3000 patients treated with omeprazole in long-term clinical trials. The incidence of ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in these studies increased with time; however, no case of ECL cell carcinoids, <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span>, or neoplasia has been found in these patients. These studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions. </p>
<p><span class="Italics">Serum Gastrin Effects </span></p>
<p>In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily dosing administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. No further increase in serum gastrin occurred with continued treatment. In comparison with histamine H2-receptor antagonists, the median increases produced by 20 mg doses of omeprazole were higher (1.3 to 3.6 fold vs. 1.1 to 1.8 fold increase). Gastrin values returned to pretreatment levels, usually within 1 to 2 weeks after discontinuation of therapy.</p>
<p><span class="Italics">Other Effects </span></p>
<p>Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.</p>
<p>No effect on gastric emptying of the solid and liquid components of a test meal was demonstrated after a single dose of omeprazole 90 mg. In healthy subjects, a single I.V. dose of omeprazole (0.35 mg/kg) had no effect on intrinsic factor secretion. No systematic dose-dependent effect has been observed on basal or stimulated pepsin output in humans. However, when intragastric pH is maintained at 4.0 or above, basal pepsin output is low, and pepsin activity is decreased.</p>
<p>As do other agents that elevate intragastric pH, omeprazole administered for 14 days in healthy subjects produced a significant increase in the intragastric concentrations of viable bacteria. The pattern of the bacterial species was unchanged from that commonly found in saliva. All changes resolved within three days of stopping treatment.</p>
<p>The course of Barrett’s esophagus in 106 patients was evaluated in a U.S. double-blind controlled study of omeprazole 40 gm b.i.d. for 12 months followed by 20 mg b.i.d. for 12 months or ranitidine 300 mg b.i.d. for 24 months. No clinically significant impact on Barrett’s mucosa by antisecretory therapy was observed. Although neosquamous epithelium developed during antisecretory therapy, complete elimination of Barrett’s mucosa was not achieved. No significant difference was observed between treatment groups in development of <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span> in Barrett’s mucosa and no patient developed esophageal carcinoma during treatment. No significant differences between treatment groups were observed in development of ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, corpus <span class="product-label-link" type="condition" conceptid="192667" conceptname="Atrophic gastritis">atrophic gastritis</span>, corpus intestinal <span class="product-label-link" type="condition" conceptid="4070551" conceptname="Metaplasia">metaplasia</span>, or colon <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> exceeding 3 mm in diameter.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="inv-ebe41193-02a0-44ef-bef7-e6903babf2bc"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">Absorption</span></p>
<p>In separate <span class="Italics">in vivo </span>bioavailability studies, when omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> oral suspension and capsules are administered on an empty stomach 1 hour prior to a meal, the absorption of omeprazole is rapid, with mean peak plasma levels (% CV) of omeprazole being 1954 ng/mL (33%) and 1526 ng/mL (49%), respectively, and time to peak of approximately 30 minutes (range 10-90 min) after a single-dose or repeated-dose administration. </p>
<p>Following single or repeated once daily dosing, peak plasma concentrations of omeprazole from omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> are approximately proportional from 20 to 40 mg doses, but a greater than linear mean AUC (three-fold increase) is observed when doubling the dose to 40 mg. The bioavailability of omeprazole from omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> increases upon repeated administration.</p>
<p>When omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is administered 1 hour after a meal, the omeprazole AUC is reduced by approximately 24% relative to administration 1 hour prior to a meal.</p>
<p><span class="Italics">Distribution</span></p>
<p>Omeprazole is bound to plasma proteins. Protein binding is approximately 95%.</p>
<p><span class="Italics">Metabolism</span></p>
<p>Following single-dose oral administration of omeprazole, the majority of the dose (about 77%) is eliminated in urine as at least six metabolites. Two metabolites have been identified as hydroxyomeprazole and the corresponding carboxylic acid. The remainder of the dose was recoverable in feces. This implies a significant biliary excretion of the metabolites of omeprazole. Three metabolites have been identified in plasma – the sulfide and sulfone derivatives of omeprazole, and hydroxyomeprazole. These metabolites have very little or no antisecretory activity.</p>
<p><span class="Italics">Excretion </span></p>
<p>Following single-dose oral administration of omeprazole, little if any, unchanged drug is excreted in urine. The mean plasma omeprazole half-life in healthy subjects is approximately 1 hour (range 0.4 to 3.2 hours) and the total body clearance is 500-600 mL/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-2c8fcb5d-1ef3-4ed3-a4d4-94bb5684e59d"></a><a name="section-11.4"></a><p></p>
<h2>Special Populations </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-642612f2-729f-4972-8c3f-006a049653b8"></a><a name="section-11.4.1"></a><p></p>
<h3><span class="Bold">Geriatric</span></h3>
<p class="First">The elimination rate of omeprazole was somewhat decreased in the elderly, and bioavailability was increased. Omeprazole was 76% bioavailable when a single 40-mg oral dose of omeprazole (buffered solution) was administered to healthy elderly subjects, versus 58% in young subjects given the same dose. Nearly 70% of the dose was recovered in urine as metabolites of omeprazole and no unchanged drug was detected. The plasma clearance of omeprazole was 250 mL/min (about half that of young subjects) and its plasma half-life averaged one hour, similar to that of young healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-02dcf905-4352-42c5-a683-fc95f3111b98"></a><a name="section-11.4.2"></a><p></p>
<h3><span class="Bold">Pediatric</span></h3>
<p class="First">The pharmacokinetics of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> have not been studied in patients &lt; 18 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-2c81d9fb-1872-4f1a-9e4c-badf0f309d49"></a><a name="section-11.4.3"></a><p></p>
<h3><span class="Bold">Gender</span></h3>
<p class="First">There are no known differences in the absorption or excretion of omeprazole between males and females.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-103f8338-7aa2-45ca-9c4e-74ce0fec4cdf"></a><a name="section-11.4.4"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></h3>
<p class="First">In patients with chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, the bioavailability of omeprazole from a buffered solution increased to approximately 100% compared to an I.V. dose, reflecting decreased first-pass effect, and the mean plasma half-life of the drug increased to nearly 3 hours compared to the mean half-life of 1 hour in normal subjects. Plasma clearance averaged 70 mL/min, compared to a value of 500-600 mL/min in normal subjects. Dose reduction, particularly where maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> is indicated, for the hepatically impaired should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-c7c2e473-746c-4028-a9fd-0ab33ba8a6b0"></a><a name="section-11.4.5"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span> </span></h3>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span>, whose creatinine clearance ranged between 10 and 62 mL/min/1.73 m <span class="Sup">2</span>, the disposition of omeprazole from a buffered solution was very similar to that in healthy subjects, although there was a slight increase in bioavailability. Because urinary excretion is a primary route of excretion of omeprazole metabolites, their elimination slowed in proportion to the decreased creatinine clearance. No dose reduction is necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-c3a4e127-db0b-45d9-8394-f6793e882bc5"></a><a name="section-11.4.6"></a><p></p>
<h3><span class="Bold">Asians </span></h3>
<p class="First">In pharmacokinetic studies of single 20-mg omeprazole doses, an increase in AUC of approximately four-fold was noted in Asian subjects compared to Caucasians. Dose adjustment, particularly where maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> is indicated, for the hepatically impaired and Asian subjects should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-d49fc7df-b5cd-4adb-95bd-e3f32d921f3e"></a><a name="section-11.4.7"></a><p></p>
<h3><span class="Bold">Drug-Drug Interactions </span></h3>
<p class="First">When omeprazole 40 mg was given once daily in combination with clarithromycin 500 mg every 8 hours to healthy adult male subjects, the steady-state plasma concentrations of omeprazole were increased by the concomitant administration of clarithromycin [C <span class="Sub">max</span>, AUC(0 to 24) and T½ increased 30%, 89%, and 34%, respectively].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="inv-bd53830d-c0a0-4a62-a888-401c944c1def"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="inv-305142b2-b109-4fca-b36f-438f2fc1089d"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis and Mutagenesis and Impairment Of Fertility</h2>
<p class="First">In two 24-month carcinogenicity studies in rats, omeprazole at daily doses of 1.7, 3.4, 13.8, 44.0 and 140.8 mg/kg/day (approximately 0.35 to 28.5 times the human dose of 40 mg/day, based on body surface area) produced gastric ECL cell carcinoids in a dose-related manner in both male and female rats; the incidence of this effect was markedly higher in female rats, which had higher blood levels of omeprazole. Gastric carcinoids seldom occur in the untreated rat. In addition, ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was present in all treated groups of both sexes. In one of these studies, female rats were treated with 13.8 mg omeprazole/kg/day (approximately 2.8 times the human dose of 40 mg/day, based on body surface area) for one year, then followed for an additional year without the drug. No carcinoids were seen in these rats. An increased incidence of treatment-related ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was observed at the end of one year (94% treated vs 10% controls). By the second year the difference between treated and control rats was much smaller (46% vs 26%) but still showed more <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in the treated group. Gastric adenocarcinoma was seen in one rat (2%). No similar tumor was seen in male or female rats treated for two years. For this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of rat no similar tumor has been noted historically, but a finding involving only one tumor is difficult to interpret. In a 52-week toxicity study in Sprague-Dawley rats, brain <span class="product-label-link" type="condition" conceptid="4298902" conceptname="Astrocytoma">astrocytomas</span> were found in a small number of males that received omeprazole at dose levels of 0.4, 2, and 16 mg/kg/day (about 0.1 to 3.3 times the human dose of 40 mg/day, based on body surface area). No <span class="product-label-link" type="condition" conceptid="4298902" conceptname="Astrocytoma">astrocytomas</span> were observed in female rats in this study. In a 2-year carcinogenicity study in Sprague-Dawley rats, no <span class="product-label-link" type="condition" conceptid="4298902" conceptname="Astrocytoma">astrocytomas</span> were found in males and females at the high dose of 140.8 mg/kg/day (about 28.5 times the human dose of 40 mg/day, based on body surface area). A 78-week mouse carcinogenicity study of omeprazole did not show increased tumor occurrence, but the study was not conclusive. A 26-week p53 (+/-) transgenic mouse carcinogenicity study was not positive.</p>
<p>Omeprazole was positive for clastogenic effects in an in vitro human lymphocyte chromosomal aberration assay, in one of two <span class="Italics">in vivo </span>mouse micronucleus tests, and in an <span class="Italics">in vivo </span>bone marrow cell chromosomal aberration assay. Omeprazole was negative in the <span class="Italics">in vitro </span>Ames Test, an <span class="Italics">in vitro </span>mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell forward mutation assay and an <span class="Italics">in vivo </span>rat liver DNA damage assay.</p>
<p>In 24-month carcinogenicity studies in rats, a dose-related significant increase in gastric <span class="product-label-link" type="condition" conceptid="4304399" conceptname="Carcinoid tumor">carcinoid tumors</span> and ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was observed in both male and female animals [See <span class="Bold">Warnings and Precautions </span>(<a href="#inv-b3398a91-b0fa-42ca-8f6e-d94a4b7d3678">5</a><span class="Bold">)</span>] <span class="product-label-link" type="condition" conceptid="4304399" conceptname="Carcinoid tumor">Carcinoid tumors</span> have also been observed in rats subjected to fundectomy or long-term treatment with other proton pump inhibitors or high doses of H<span class="Sub">2</span>-receptor antagonists.</p>
<p>Omeprazole at oral doses up to 138 mg/kg/day (about 28 times the human dose of 40 mg/day, based on body surface area) was found to have no effect on the fertility and general reproductive performance in rats.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="inv-fbdd1490-28b2-48bf-b609-40f93152da7e"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Pharmacology and/or Toxicology Section </h2>
<p class="First"><span class="Italics">Reproductive Toxicology Studie</span>s </p>
<p>Reproduction studies conducted in pregnant rats at omeprazole doses up to 138 mg/kg/day (about 28 times the human dose of 40 mg/day, based on body surface area) and in pregnant rabbits at doses up to 69 mg/kg/day (about 28 times the human dose of 40 mg/day, based on body surface area) did not disclose any evidence for a teratogenic potential of omeprazole.</p>
<p>In rabbits, omeprazole in a dose range of 6.9 to 69 mg/kg/day (about 2.8 to 28 times the human dose of 40 mg/day, based on body surface area) produced dose-related increases in embryo-lethality, fetal resorptions and pregnancy disruptions. In rats, dose-related embryo/fetal toxicity and postnatal developmental toxicity were observed in offspring resulting from parents treated with omeprazole at 13.8 to 138.0 mg/kg/day (about 2.8 to 28 times the human dose of 40 mg/day, based on body surface area).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="inv-2d81c3d2-973a-4340-a042-d22e4d46e49d"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-c9df644e-12a0-4da8-acce-da07022113f7"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Disease </h2>
<p class="First">Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> – In a multicenter, double-blind, placebo controlled study of 147 patients with endoscopically documented <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, the percentage of patients healed (per protocol) at 2 and 4 weeks was significantly higher with omeprazole 20 mg once a day than with placebo (p <span class="Underline">&lt;</span> 0.01). (See <span class="Bold">Table 5</span>.) </p>
<a name="_Refinv-e5bd8a92-c405-436f-a44b-db293844"></a><table width="100%">
<caption><span>Table 5: Treatment of Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> % of Patients Healed</span></caption>
<col width="23%">
<col width="23%">
<col width="23%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="3" valign="top">* (p &lt; 0.01)</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole       </span>	20<span class="Bold">	 mg a.m.      </span>	(n <span class="Bold">	= 99)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	P<span class="Bold">	lacebo      </span>	a.<span class="Bold">	m.       </span>	(n <span class="Bold">	= 48)      </span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Week 2          Week 4 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">41*         75*</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13         27</p></td>
</tr>
</tbody>
</table>
<p>Complete daytime and nighttime <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief occurred significantly faster (p ≤ 0.01) in patients treated with omeprazole 20 mg than in patients treated with placebo. At the end of the study, significantly more patients who had received omeprazole had complete relief of daytime <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (p ≤ 0.05) and nighttime <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (p ≤ 0.01).</p>
<p>In a multicenter, double-blind study of 293 patients with endoscopically documented <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, the percentage of patients healed (per protocol) at 4 weeks was significantly higher with omeprazole 20 mg once a day than with ranitidine 150 mg b.i.d. (p &lt; 0.01). (See <span class="Bold">Table 6</span>) </p>
<a name="_Refinv-666d0ac8-86de-4162-a026-483bf765"></a><table width="100%">
<caption><span>Table 6: Treatment of Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> % of Patients Healed</span></caption>
<col width="23%">
<col width="23%">
<col width="23%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="6" valign="top">* (p &lt; 0.01)</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole       </span>	20<span class="Bold">	 mg a.m      </span>	 (n<span class="Bold">	 = 145)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	R<span class="Bold">	anitidine       </span>	15<span class="Bold">	0 mg b.i.d      </span>	(n <span class="Bold">	= 148)      </span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Week 2          Week 4 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">	4<span class="Bold">	2       </span>	82<span class="Bold">	*      </span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">	3<span class="Bold">	4       </span>	63                                  </p></td>
</tr>
</tbody>
</table>
<p>Healing occurred significantly faster in patients treated with omeprazole than in those treated with ranitidine 150 mg b.i.d. (p &lt; 0.01).</p>
<p>In a foreign multinational randomized, double-blind study of 105 patients with endoscopically documented <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, 40 mg and 20 mg of omeprazole were compared to 150 mg b.i.d. of ranitidine at 2, 4 and 8 weeks. At 2 and 4 weeks both doses of omeprazole were statistically superior (per protocol) to ranitidine, but 40 mg was not superior to 20 mg of omeprazole, and at 8 weeks there was no significant difference between any of the active drugs. (See <span class="Bold">Table 7</span>)</p>
<a name="_Refinv-d68b4bd1-4129-4939-b5a1-fbaed49e"></a><table width="100%">
<caption><span>Table 7: Treatment of Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> % of Patients Healed</span></caption>
<col width="8%">
<col width="22%">
<col width="9%">
<col width="20%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="10" valign="top">* (p≤ 0.01)</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule"><p class="First">	O<span class="Bold">	meprazole       </span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule"><p class="First">	R<span class="Bold">	anitidine       </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> </p></td>
<td class="Botrule Rrule"><p class="First">40 mg          (n = 36) </p></td>
<td class="Botrule Rrule"><p class="First">20 mg          (n = 34) </p></td>
<td class="Botrule Rrule"><p class="First">150 mg b.i.d.          (n = 35) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Week 2          Week 4          Week 8 </p></td>
<td class="Botrule Rrule"><p class="First">83*          100*         100 </p></td>
<td class="Botrule Rrule"><p class="First">83*         97*         100 </p></td>
<td class="Botrule Rrule"><p class="First">53         82          94 </p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-9b1e446d-cabb-4213-b3cf-5425c9b66fbf"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> </h2>
<p class="First">In a U.S. multicenter, double-blind study of omeprazole 40 mg once a day, 20 mg once a day, and placebo in 520 patients with endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, the following results were obtained. (See <span class="Bold">Table 8</span>)</p>
<a name="_Refinv-13fe30dd-b67b-4016-b668-aeadef90"></a><table width="100%">
<caption><span>Table 8: Treatment of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> % of Patients Healed (All Patients Treated)</span></caption>
<col width="9%">
<col width="22%">
<col width="22%">
<col width="18%">
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="4" valign="top">** (p &lt; 0.01) Omeprazole 40 mg or 20 mg versus placebo</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="4" valign="top">+ (p&lt; 0.05) Omeprazole 40 mg versus 20 mg</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	40<span class="Bold">	 mg q.d.      </span>	(n <span class="Bold">	= 214)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	20<span class="Bold">	 mg q.d.      </span>	(n <span class="Bold">	= 202)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	 	Pl<span class="Bold">	acebo      </span>	(n <span class="Bold">	= 104)      </span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Week 4       Week 8 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">	5<span class="Bold">	5.6**       </span>	82<span class="Bold">	.7**,+       </span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">	4<span class="Bold">	7.5**       </span>	74<span class="Bold">	.8**       </span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">	3<span class="Bold">	0.8       </span>	48<span class="Bold">	.1       </span></p></td>
</tr>
</tbody>
</table>
<p>For the stratified groups of patients with <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> size less than or equal to 1 cm, no difference in healing rates between 40 mg and 20 mg was detected at either 4 or 8 weeks. For patients with <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> size greater than 1 cm, 40 mg was significantly more effective than 20 mg at 8 weeks.</p>
<p>In a foreign, multinational, double-blind study of 602 patients with endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, omeprazole 40 mg once a day, 20 mg once a day, and ranitidine 150 mg twice a day were evaluated. (See <span class="Bold">Table 9</span>.) </p>
<a name="_Refinv-2d5b2fcc-f981-4820-8978-150eeab6"></a><table width="100%">
<caption><span>Table 9: Treatment of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> % of Patients Healed  (All Patients Treated)</span></caption>
<col width="17%">
<col width="22%">
<col width="22%">
<col width="20%">
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="8" valign="top">** (p &lt; 0.01) Omeprazole 40 mg versus ranitidine</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="8" valign="top">++ (p &lt; 0.01) Omeprazole 40 mg versus 20 mg</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	40<span class="Bold">	 mg q.d.      </span>	(n <span class="Bold">	= 187)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	20<span class="Bold">	 mg q.d.      </span>	(n <span class="Bold">	= 200)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	R<span class="Bold">	anitidine      </span>	15<span class="Bold">	0 mg b.i.d.      </span>	(n <span class="Bold">	= 199)      </span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Week 4       Week 8 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">78.1**,++ 91.4**,++</p></td>
<td class="Botrule Rrule" align="center"><p class="First">63.5      81.5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">56.3      78.4</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-dd8b66ee-aef7-4cfd-8363-f520810e0ae9"></a><a name="section-13.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) </h2>
<p class="First"><span class="Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>-</span>A placebo controlled study was conducted in Scandinavia to compare the efficacy of omeprazole 20 mg or 10 mg once daily for up to 4 weeks in the treatment of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and other symptoms in <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> patients without <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>. Results are shown in<span class="Bold"> Table 10</span>. </p>
<a name="_Refinv-8ab76919-a2f5-4072-bbb3-618e974a"></a><table width="100%">
<caption><span>Table 10: % Successful Symptomatic Outcome<span class="Sup">a</span></span></caption>
<col width="12%">
<col width="22%">
<col width="22%">
<col width="18%">
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="4" valign="top">a Defined as complete resolution of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></td></tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top">* (p &lt; 0.005) versus 10 mg</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="4" valign="top">† (p &lt; 0.005) versus placebo</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	20<span class="Bold">	 mg a.m.      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole       </span>	10<span class="Bold">	 mg a.m.      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	P<span class="Bold">	lacebo       </span>	a.<span class="Bold">	m.      </span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">All patients              Patients with confirmed <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">46*,†      (n = 205)      56*,†      (n = 115)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">31†      (n = 199)      36†      (n = 109)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13      (n = 105)      14      (n = 59)</p></td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> -In a U.S. multicenter double-blind placebo controlled study of 40 mg or 20 mg of omeprazole delayed-released capsules in patients with symptoms of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> and endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> of grade 2 or above, the percentage healing rates (per protocol) were as shown in <span class="Bold">Table 11</span>. </p>
<a name="_Refinv-860711e0-ec4f-4e66-b597-1d13a485"></a><table width="100%">
<caption><span>Table 11: % Patients Healed</span></caption>
<col width="15%">
<col width="22%">
<col width="22%">
<col width="18%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="8" valign="top">*(p &lt; 0.01) Omeprazole versus placebo.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	40<span class="Bold">	 mg      </span>	(n <span class="Bold">	= 87)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	20<span class="Bold">	 mg      </span>	(n <span class="Bold">	= 83)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	P<span class="Bold">	lacebo       </span>	       	(n <span class="Bold">	= 43)      </span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Week 4       Week 8 </p></td>
<td class="Botrule Rrule" align="center"><p class="First">45*      75*</p></td>
<td class="Botrule Rrule" align="center"><p class="First">39*      74*</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7      14</p></td>
</tr>
</tbody>
</table>
<p>In this study, the 40-mg dose was not superior to the 20-mg dose of omeprazole in the percentage healing rate. Other controlled clinical trials have also shown that omeprazole is effective in severe <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. In comparisons with histamine H <span class="Sub">2</span>-receptor antagonists in patients with <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>, grade 2 or above, omeprazole in a dose of 20 mg was significantly more effective than the active controls. Complete daytime and nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> relief occured significantly faster (p&lt; 0.01) in patients treated with omeprazole than in those taking placebo or histamine H<span class="Sub">2</span>-receptor antagonists. </p>
<p>In this and five other controlled <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> studies, significantly more patients taking 20 mg omeprazole (84%) reported complete relief of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> symptoms than patients receiving placebo (12%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-50c7f20c-8404-4628-8f77-f15057ea525b"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Long Term Maintenance Treatment of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">Erosive Esophagitis</span> </h2>
<p class="First">In a U.S. double-blind, randomized, multicenter, placebo controlled study, two dose regimens of omeprazole were studied in patients with endoscopically confirmed healed <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>. Results to determine maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> are shown in <span class="Bold">Table 12</span>. </p>
<a name="_Refinv-434e28b7-0f9e-4762-bc5a-4b9b0e59"></a><table width="100%">
<caption><span>Table 12: Life Table Analysis</span></caption>
<col width="21%">
<col width="22%">
<col width="22%">
<col width="18%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*(p &lt; 0.01) Omeprazole 20 mg once daily versus Omeprazole 20 mg 3 consecutive days per week or placebo.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	20<span class="Bold">	 mg q.d.      </span>	(n <span class="Bold">	= 138)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	20<span class="Bold">	 mg 3 days per week      </span>	(n <span class="Bold">	= 137)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	P<span class="Bold">	lacebo      </span>	(n<span class="Bold">	 = 131)      </span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Percent in endoscopic remission at 6 months </p></td>
<td class="Botrule Rrule" align="center"><p class="First">70*</p></td>
<td class="Botrule Rrule" align="center"><p class="First">34</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11</p></td>
</tr>
</tbody>
</table>
<p>In an international multicenter double-blind study, omeprazole 20 mg daily and 10 mg daily were compared to ranitidine 150 mg twice daily in patients with endoscopically confirmed healed <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>. <span class="Bold">Table 13</span> provides the results of this study for maintenance of healing of <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>.</p>
<a name="_Refinv-a44f113d-9e91-4d52-b5ae-962d687f"></a><table width="100%">
<caption><span>Table 13: Life Table Analysis</span></caption>
<col width="23%">
<col width="22%">
<col width="22%">
<col width="20%">
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="8" valign="top">* (p = 0.01) Omeprazole 20 mg once daily versus Omeprazole 10 mg once daily or Ranitidine</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="8" valign="top">‡ (p = 0.03) Omeprazole 10 mg once daily versus Ranitidine</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	20<span class="Bold">	 mg q.d.      </span>	(n <span class="Bold">	= 131)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	O<span class="Bold">	meprazole      </span>	10<span class="Bold">	 mg q.d.      </span>	(n <span class="Bold">	= 133)      </span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">	R<span class="Bold">	anitidine      </span>	(n<span class="Bold">	 = 128)      </span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Percent in endoscopic remission at 12 months </p></td>
<td class="Botrule Rrule" align="center"><p class="First">77*</p></td>
<td class="Botrule Rrule" align="center"><p class="First">58<span class="Sup">‡</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">46</p></td>
</tr>
</tbody>
</table>
<p>In patients who initially had grades 3 or 4 <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span>, for maintenance after healing 20 mg daily of omeprazole was effective, while 10 mg did not demonstrate effectiveness.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="inv-7499db53-9296-4207-8509-380bf9154d72"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Friedman JM and Polifka JE. Omeprazole. In: Teratogenic Effects of Drugs. A Resource for Clinicians (TERIS). 2nd ed. Baltimore, MD: The Johns Hopkins University Press 2000; p. 516. </dd>
<dt>2.</dt>
<dd>Kallen BAJ. Use of omeprazole during pregnancy – no hazard demonstrated in 955 infants exposed during pregnancy. Eur Obstet Gynecol Reprod Biol 2001; 96(1):63-8. </dd>
<dt>3.</dt>
<dd>Ruigomez A, Rodriguez LUG, Cattaruzzi C, et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 1999; 150:476-81. </dd>
<dt>4.</dt>
<dd>Lalkin A, Loebstein, Addis A, et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol 1998; 179:727-30. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="inv-e51e7e9e-8029-45ce-9a90-68c4b3c1ad66"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is available as hard gelatin capsule containing 20 mg of omeprazole and 1100 mg of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. The capsule consists of a white opaque body printed with par/397 in black ink and light blue opaque cap.</p>
<p>NDC 49884-397-11Bottles of 30 capsules</p>
<p>NDC 49884-397-05Bottles of 500 capsules</p>
<p>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is available as hard gelatin capsule containing 40 mg of omeprazole and 1100 mg of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. The capsule consists of a white opaque body printed with par/455 in black ink and blue opaque cap.</p>
<p>NDC 49884-455-11Bottles of 30 capsules</p>
<p>NDC 49884-455-05Bottles of 500 capsules</p>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-770277e6-0ffa-4031-92e3-79de95807f8d"></a><a name="section-15.1"></a><p></p>
<h2>Storage </h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15 -30°C (59 -86°F). [See USP Controlled Room Temperature].</p>
<p>Keep this medication out of the hands of children. Keep container tightly closed. Protect from light and moisture.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="inv-d3827d84-de06-41b8-8d45-9724650136ba"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling</p>
<p>Instruct patients that omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> should be taken on an empty stomach at least one hour prior to a meal. [See <span class="Bold">Dosage and Administration </span>(<a href="#inv-b3398a91-b0fa-42ca-8f6e-d94a4b7d3678">2</a>)] </p>
<p>Instruct patients in Directions for Use as follows:</p>
<p>Capsules: Swallow intact capsule with water. DO NOT USE OTHER LIQUIDS. DO NOT OPEN CAPSULE AND SPRINKLE CONTENTS INTO FOOD.</p>
<p>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is available either as 40 mg or 20 mg capsules with 1100 mg sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</p>
<p>Patients should be instructed not to substitute omeprazole and sodium capsules for other omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> dosage forms because different dosage forms contain different amounts of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. [See <span class="Bold">Dosage and Administration </span>(<a href="#inv-b3398a91-b0fa-42ca-8f6e-d94a4b7d3678">2</a>)] </p>
<p>Patients should be advised that since both the 20 mg and 40 mg <span class="Bold">capsules </span>contain the same amount of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (1100 mg), two capsules of 20 mg are <span class="Bold">not </span>equivalent to one capsule of omeprazole and sodium 40 mg; therefore, two 20 mg capsules of omeprazole and sodium should not be substituted for one capsule of omeprazole and sodium 40 mg. [See <span class="Bold">Dosage and Administration </span>(<a href="#inv-b3398a91-b0fa-42ca-8f6e-d94a4b7d3678">2</a>)] </p>
<p>Patients should be advised that this drug is not approved for patients less than 18 years of age. [See <span class="Bold">Pediatric Use </span>(<a href="#inv-b3398a91-b0fa-42ca-8f6e-d94a4b7d3678">8.4</a>)] </p>
<p>Patients on a sodium restricted diet or patients at risk of developing <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) should be informed of the sodium content of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> Capsules (304 mg per capsule) . Patients should be informed that chronic use of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> may cause problems and increased sodium intake can cause <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. If this occurs, they should contact their healthcare provider. [ <span class="Bold">See Warnings and Precautions </span>(<a href="#inv-b3398a91-b0fa-42ca-8f6e-d94a4b7d3678">5.3</a>)] </p>
<p>Patients should be informed that the most frequent adverse reactions associated with omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>. [See <span class="Bold">Adverse Reactions </span>(<a href="#inv-b3398a91-b0fa-42ca-8f6e-d94a4b7d3678">6</a>)] </p>
<p>Pregnant women should be advised that a harmful effect of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> on the fetus can not be ruled out and that the drug should be used with caution during pregnancy. [See <span class="Bold">Pregnancy </span>(<a href="#inv-b3398a91-b0fa-42ca-8f6e-d94a4b7d3678">8.1</a>)] </p>
<p>Patients should be advised to use this drug with caution if they are regularly taking calcium supplements. [See <span class="Bold">Warnings and Precautions </span>(<a href="#inv-b3398a91-b0fa-42ca-8f6e-d94a4b7d3678">5.3</a>)] </p>
<p>Advise patients to immediately report and seek care for any cardiovascular or neurological symptoms including <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span> as these may be signs of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>. [See <span class="Bold">Warnings and Precautions</span> (<a href="#_Ref">5.5</a><span class="Bold">)].</span></p>
<p>Manufactured by:</p>
<p><span class="Bold">PAR PHARMACEUTICAL COMPANIES INC.</span></p>
<p><span class="Bold">Spring Valley, NY 10977</span></p>
<p>Revised 03/2012</p>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-e0afb2ad-e5bd-433d-820a-3749165fcaa3"></a><a name="section-16.1"></a><p></p>
<h2>FDA-APPROVED PATIENT LABELING </h2>
<p class="First"><span class="Bold">Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Capsules</span></p>
<p>Read the Patient Information that comes with omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your healthcare provider about your medical condition or treatment.</p>
<p><span class="Bold">What is Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> ?</span></p>
<p>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is a medicine called a proton pump inhibitor (PPI). Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> reduces the amount of acid in your stomach.</p>
<p>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> are used in adults for:</p>
<dl>
<dt>•</dt>
<dd>for 4 weeks to heal <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the first part of the small bowel (<span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>).  Your doctor may prescribe an additional 4 weeks of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. </dd>
<dt>•</dt>
<dd>for up to 8 weeks for healing <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span> </dd>
<dt>•</dt>
<dd>for up to 4 weeks to treat <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and other symptoms that happen with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>). </dd>
</dl>
<p><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> is a chronic condition (lasts a long time) that occurs when acid from the stomach backs up into the esophagus (food pipe) causing symptoms, such as <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, or damage to the lining of the esophagus. Common symptoms include frequent <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> that will not go away, a sour or bitter taste in the mouth, and difficulty swallowing.</p>
<dl>
<dt>•</dt>
<dd>for up to 8 weeks to heal acid-related damage to the lining of the esophagus (called <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> or EE) </dd>
<dt>•</dt>
<dd>to maintain healing of the esophagus. Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> has not been studied for treatment lasting longer than 12 months (1 year)  </dd>
</dl>
<p>It is not known if omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> are safe and effective in children and adolescents less than 18 years of age.</p>
<p>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor.</p>
<p><span class="Bold">Who should not take Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span>? </span></p>
<p>Do not take omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> if you:</p>
<dl>
<dt>•</dt>
<dd>are allergic to any of the ingredients in omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.  See the end of this leaflet for a complete list of ingredients in omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. </dd>
<dt>•</dt>
<dd>are allergic to any other PPI medicine. </dd>
</dl>
<p><span class="Bold">What should I tell my doctor before I take Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span>? </span></p>
<p><span class="Bold">Before you take Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Capsules, tell your doctor if you</span>:</p>
<dl>
<dt>•</dt>
<dd>have been told that you have low magnesium levels in your blood.</dd>
<dt>•</dt>
<dd>have any liver problems. </dd>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </dd>
<dt>•</dt>
<dd>have Bartter’s syndrome (a rare kidney disorder). </dd>
<dt>•</dt>
<dd>have any allergies. </dd>
<dt>•</dt>
<dd>are pregnant or planning to become pregnant.  It is not known if omeprazole and  sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.<dl>
<dt>•</dt>
<dd>are breastfeeding or planning to breastfeed.  You and your doctor should decide if you will take omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> or breastfeed.  You should not do both.  Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (a part of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> ) should be used with caution in nursing mothers.</dd>
</dl>
</dd>
</dl>
<p>Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> may affect how other medicines work, and other medicines may affect how omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> work. This can cause serious side effects. Know the medicines that you take. Keep a list of them with you and show it to your doctor when you get a new medicine. Be sure to tell your doctor if you are taking:</p>
<dl>
<dt>•</dt>
<dd>diazepam (Valium)® </dd>
<dt>•</dt>
<dd>warfarin (Coumadin) ®</dd>
<dt>•</dt>
<dd>phenytoin (Dilantin)® </dd>
<dt>•</dt>
<dd>cyclosporine</dd>
<dt>•</dt>
<dd>disulfiram (Antabuse)® </dd>
<dt>•</dt>
<dd>benzodiazepines</dd>
<dt>•</dt>
<dd>ketoconazole (Nizoral)® </dd>
<dt>•</dt>
<dd>ampicillin sodium (Unazyn)® or ampicillin trihydrate (Principen)® </dd>
<dt>•</dt>
<dd>iron salts </dd>
<dt>•</dt>
<dd>digoxin</dd>
<dt>•</dt>
<dd>voriconazole (Nizoral)® </dd>
<dt>•</dt>
<dd>atazanavir (Reyataz)® </dd>
<dt>•</dt>
<dd>nelfinavir (Viracept)® </dd>
<dt>•</dt>
<dd>tacrolimus (Prograf)® </dd>
<dt>•</dt>
<dd>saquinavir (Fortovase)® </dd>
<dt>•</dt>
<dd>clarithromycin </dd>
<dt>•</dt>
<dd>clopidogrel (Plavix)®</dd>
</dl>
<p><span class="Bold">How should I take Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Capsules? </span></p>
<dl>
<dt>•</dt>
<dd>Take omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> exactly as prescribed by your doctor. Do not change your dose or stop taking omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> without talking to your doctor.  Take omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> for as long as it is prescribed even if you feel better. </dd>
<dt>•</dt>
<dd>Take omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> on an empty stomach at least one hour before a meal. </dd>
<dt>•</dt>
<dd>Swallow omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> capsules whole with water. DO NOT USE OTHER LIQUIDS. Do not crush or chew the capsule.  Do not open the capsule and sprinkle contents into food.</dd>
<dt>•</dt>
<dd>Do not substitute omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> for other omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> dosage forms because different dosage forms contain different amounts of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. </dd>
<dt>•</dt>
<dd>If you forget to take a dose of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, take it as soon as you remember. If it is almost time for your next dose, do not take the missed dose. Take the next dose at your regular time.  Do not take two doses to make up for a missed dose. </dd>
<dt>•</dt>
<dd>Do not substitute two 20mg capsules for one 40mg capsule of omeprazole sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> because you will receive twice the amount of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.  Talk to your doctor if you have any questions.</dd>
<dt>•</dt>
<dd>If you take too much omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, call your doctor or Poison Control Center right away, or go to the emergency room. </dd>
<dt>•</dt>
<dd>Your doctor may prescribe antibiotic medicines with omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> to help treat a stomach <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and heal stomach-area (duodenal) <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> that are caused by bacteria called H. pylori. Make sure you read the patient information that comes with an antibiotic before you start taking it. </dd>
</dl>
<p><span class="Bold">What are the possible side effects of Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span>? </span></p>
<p>Omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> may cause serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. See the end of this leaflet for a complete list of ingredients in omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> capsules.</p>
<p><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </span>Tell your doctor if you get any of the following symptoms with Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> : </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> </dd>
<dt>•</dt>
<dd>face <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span> </dd>
</dl>
<p>Your doctor may stop omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> if these symptoms happen.</p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Low magnesium levels in your body.</span>  This problem can be serious. Low magnesium can happen in some people who take a proton pump inhibitor medicine for at least 3 months.  If low magnesium levels happen, it is usually after a year of treatment.  You may or may not have symptoms of low magnesium. </dd>
</dl>
<p>Tell your doctor right away if you have any of these symptoms:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>•</dt>
<dd>abnormal  or fast heartbeat</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span></dd>
<dt>•</dt>
<dd>jerking movements or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> (<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of the hands and feet</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span></dd>
<dt>•</dt>
<dd>spasm of the voice box</dd>
</dl>
<p>Your doctor may check the level of magnesium in your body before you start taking omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, or during treatment if you will be taking omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> for a long period of time.</p>
<p>The most common side effects with omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> include:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </dd>
<dt>•</dt>
<dd>gas </dd>
</dl>
<p>Using omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> for a long time may cause problems like <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Tell your doctor if this happens.</p>
<p>If you are on a low sodium diet or at risk of developing <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF), you and your doctor should decide if you will take omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</p>
<p>People who are taking multiple daily doses of proton pump inhibitor medicines for a long period of time may have an increased risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist or spine.</p>
<p>Tell your doctor about any side effects that bother you or that do not go away. These are not all the possible side effects of omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Omeprazole and  Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span>? </span></p>
<dl>
<dt>•</dt>
<dd>Store omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> in a dry place at room temperature, 59°F to 86°F (15°C to 30°C). </dd>
</dl>
<p><span class="Bold">Keep omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and all medicines out of the reach of children. </span></p>
<p><span class="Bold">General Information about Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> </span></p>
<p>Medicines are sometimes prescribed for conditions other than those described in patient information leaflets. Do not use omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> for any condition for which it was not prescribed by your doctor. Do not give omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> to other people, even if they have the same symptoms as you. It may harm them.</p>
<p>This leaflet summarizes the most important information about omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. If you would like more information, talk to your doctor. You can also ask your doctor or pharmacist for information about omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> that is written for healthcare professionals.</p>
<p><span class="Bold">Patients Instructions for Use</span></p>
<p>For instructions on taking omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> capsules, please see</p>
<p>“How should I take Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Capsules??</p>
<p><span class="Bold">What are the ingredients in Omeprazole and Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Capasules? </span></p>
<p>Active Ingredients: omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span></p>
<p>Inactive ingredients: croscarmellose sodium and magnesium stearate. The capsules consist of black iron oxide, D&amp;C Yellow #10, FD&amp;C Blue #1, FD&amp;C Red #3, FD&amp;C Red #40, gelatin and titanium dioxide. In addition the ink consists of D&amp;C Yellow #10 aluminum lake, iron oxide black, n-butyl alcohol, propylene glycol, FD&amp;C Blue #2 aluminum lake, FD&amp;C Red #40 aluminum lake, FD&amp;C Blue #1 aluminum lake and shellac glaze~45% (20% esterfied) in ethanol.</p>
<p>The above-referenced trademarks are the property of their respective owners.</p>
<p>For prescription only</p>
<p>Revised March 2012</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-fa45d1b4-8b43-4364-a4d5-49e2572ef975"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL- 20MG/1100MG CONTAINER LABEL</h1>
<div class="Figure">
<a name="ID0EH4AI"></a><img alt="This is the 20 mg container label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c43b7c1e-1eb6-48b4-ba73-56e274239ae2&amp;name=20mg_Container.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-0c79e22b-eac0-4680-8e67-0e465c64df7d"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL- 40MG/1100MG CONTAINER LABEL</h1>
<div class="Figure">
<a name="ID0E54AI"></a><img alt="This is the 40 mg container label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c43b7c1e-1eb6-48b4-ba73-56e274239ae2&amp;name=40mg_Container.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OMEPRAZOLE AND SODIUM BICARBONATE 		
					</strong><br><span class="contentTableReg">omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49884-455</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OMEPRAZOLE</strong> (OMEPRAZOLE) </td>
<td class="formItem">OMEPRAZOLE</td>
<td class="formItem">40 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong> (<span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span> ION) </td>
<td class="formItem">SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></td>
<td class="formItem">1100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue (white body) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">par;455</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-455-11</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/30/2010</td>
<td class="formItem">06/30/2016</td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49884-455-05</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/30/2010</td>
<td class="formItem">06/30/2016</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078966</td>
<td class="formItem">06/30/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OMEPRAZOLE AND SODIUM BICARBONATE 		
					</strong><br><span class="contentTableReg">omeprazole and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49884-397</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OMEPRAZOLE</strong> (OMEPRAZOLE) </td>
<td class="formItem">OMEPRAZOLE</td>
<td class="formItem">20 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong> (<span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span> ION) </td>
<td class="formItem">SODIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></td>
<td class="formItem">1100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue (white body) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">par;397</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-397-11</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/30/2010</td>
<td class="formItem">06/30/2016</td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49884-397-05</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">06/30/2010</td>
<td class="formItem">06/30/2016</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078966</td>
<td class="formItem">06/30/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Par Pharmaceutical Inc.
							(092733690)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Par Pharmaceutical Inc. (092733690)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Par Pharmaceutical Inc.</td>
<td class="formItem"></td>
<td class="formItem">092733690</td>
<td class="formItem">MANUFACTURE(49884-455, 49884-397)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>68832c9f-819c-43b2-a049-ecf168297b7a</div>
<div>Set id: c43b7c1e-1eb6-48b4-ba73-56e274239ae2</div>
<div>Version: 8</div>
<div>Effective Time: 20150105</div>
</div>
</div> <div class="DistributorName">Par Pharmaceutical Inc.</div></p>
</body></html>
